Subscribe
Share
Share
Embed
Monthly clinical deep analysis in cardiac electrophysiology: AF, VT, SVT, ablation, devices, antiarrhythmic drugs, and high-impact trials. The Signal: physician-level analysis that identifies what matters in EP and translates evidence into clinical practice.
EP Edge™: The Signal is the flagship monthly podcast from EP Edge, delivering structured, expert-level interpretation for electrophysiologists, cardiologists, fellows, and clinically engaged practitioners. Each episode goes beyond summaries to integrate evidence across trials, guidelines, mechanisms, and real-world practice.
Episodes cover the full spectrum of electrophysiology, including atrial and ventricular arrhythmias, supraventricular tachycardias, antiarrhythmic pharmacology, pacing and defibrillator strategies, mapping and ablation technologies (including pulsed field ablation), and emerging data shaping clinical decision-making. This is not a news recap—it is a curated synthesis focused on what truly changes practice.
Content combines mechanistic insight, cross-trial evidence review, critical appraisal of methodology and outcomes, and practical application in the EP lab and clinic.
EP Edge™: The Signal complements the weekly EP Edge™: Journal Watch by providing deeper analysis and clinical synthesis. For patient-focused education, explore EP Edge™: Heart Talk.
Available as both podcast and newsletter via EP Edge on LinkedIn and Substack: https://epedge.substack.com/
Hello everyone and welcome back to the EP Edge podcast. This is Doctor. Niraj Sharma bringing you the November 2025 edition, issue six. Today we take a step back before we look ahead. Atrial fibrillation ablation has traveled an extraordinary road over the last three decades, a story of innovation, persistence and yes, occasional frustration.
Dr Niraj Sharma:Let's begin with where it all started. In the late 1980s and early 1990s, Doctor. James Cox introduced Cox Maze procedure, a surgical solution that literally created a maze of atrial incisions to block errant electrical wave fronts. It was elegant, logical and remarkably effective, but it required open heart surgery. The concept though laid the foundation for everything that followed.
Dr Niraj Sharma:If you could isolate or interrupt the circuits, you could restore rhythm. Then came a paradigm shifting observation from Doctor. Michel Hassaguer and colleagues in 1998. Their landmark paper identified pulmonary vein ectopy as the trigger of paroxysmal atrial fibrillation, a discovery that revolutionized our approach. The goal was no longer to carve surgical mazes, but to electrically isolate the pulmonary veins through catheter ablation.
Dr Niraj Sharma:Soon after, Doctor. Carlo Papponi and others advanced the technique with wide circumferential pulmonary vein isolation, ushering in the modern era of catheter ablation, guided by electroanatomic mapping, improved catheters, and real time imaging. Over time, our tools changed dramatically. Radiofrequency ablation dominated the early years, precise but unforgiving. Then came cryoablation, offering the simplicity of a single shot freeze and improved reproducibility.
Dr Niraj Sharma:And now we stand at the threshold of pulse field ablation, a non thermal tissue selective technology that promises safety and speed never seen before. But here's the paradox: while our energy sources have evolved, the long term success rates of atrial fibrillation ablation have not improved as much as we'd hoped. We've made enormous strides in safety, with lower rates of tamponade, stroke, and pulmonary vein stenosis, but durable rhythm control remains elusive for many, and that realization has shifted our focus. We now recognize that atrial fibrillation isn't just an electrical disorder, it's a disease of the atrial substrate. Behind every recurrence lies an evolving story of atrial myopathy, fibrosis, inflammation, and remodeling.
Dr Niraj Sharma:Emerging biomarkers from high sensitivity CRP to Galactin-three transforming GF beta and nitriuretic peptides help us understand this biology, though they add little incremental predictive power beyond what we already know clinically. Advanced MRI and electroanatomic imaging now allow us to see the atrial fibrosis that once was invisible. So as we move into this month's discussion, we ask: When atrial fibrillation ablation fails, have we truly reached the limit or are we simply targeting the wrong substrate? That's where today's EP EDGE newsletter begins. Stay with me as we explore why ablation fails, what lies beyond the pulmonary veins, and where the next frontier of rhythm control may take us.
Dr Niraj Sharma:This is Doctor. Niraj Sharma and you're listening to the EP Edge podcast. Now let's dive
AI 1:Okay. So let's unpack this deep dive into atrial fibrillation, AF catheter ablation. You know, it's really pushed towards being a first line therapy lately. But, our sources are pointing out something kind of perplexing. We've got amazing tech, RF, cryo, PFA, but the success rate seemed to have just
AI 2:stalled. That's exactly right. Yeah. It's what the research is calling a biological ceiling. You look at one year freedom from AF, even with the latest tools, it's stuck.
AI 2:Maybe 75%.
AI 1:And long term.
AI 2:Well, that's where it gets really concerning. Five years out, you can see success rates dipping below forty percent sometimes. So the issue isn't really the catheter, it's it's the biology we're up against.
AI 1:So pulmonary vein isolation, PVI, it's a necessary step, but clearly not the whole picture.
AI 2:Not the whole picture at all.
AI 1:Our mission here then is to figure out why that ceiling exists, what's holding us back, and what's next beyond just creating lesions.
AI 2:Right. So when ablation fails, it's usually more complex than just a simple electrical short circuit reappearing. Yeah. The most common trigger we see is late reconnection of those pulmonary veins. That definitely happens maybe twenty to forty percent of the time, but those reconnections, they're often just exploiting a deeper problem.
AI 1:Okay. Let's zero in on that deeper problem. The structural remodeling. People usually think fibrosis, scar tissue, but the sources flag something else too, something infiltrating.
AI 2:Yeah. Peri atrial fat. Yeah. Fat tissue around the atrium. It doesn't just sit there.
AI 2:It gets into the muscle. It's inflammatory. It actively helps keep the AF going. Think of it like, like biological kindling around the heart's chambers.
AI 1:Wow. Okay. So it's not just fixing faulty wiring. It's like the foundation itself is compromised.
AI 2:Exactly. That fat and the atrial enlargement that often comes with it, they are strong predictors that AF will come back.
AI 1:That's
AI 2:true. The data suggests that for every, say, 10 cubic centimeters increase in that fat around the left atrium, your risk and recurrence goes up by about ten percent. It's significant. We need to look at the structure, not just the electricity.
AI 1:So if that biology, that substrate is the real driver of failure, what are the warning signs clinicians see? What tells them, oh, this one might be tough?
AI 2:Well, the biggest red flag according to the sources is early recurrence. If AF comes back quickly, say within the first two months after the ablation, it's the strongest predictor of late failure down the road. Makes future failure about three times more likely.
AI 1:Okay, that's a clear marker. Are there others?
AI 2:Absolutely. Things like having persistent AF, the kind that doesn't stop on its own that bumps up the risk maybe one point seven times and then the usual suspects. Obesity, diabetes, being older, say 70, these all play a role.
AI 1:This really brings us to that paradigm shift, doesn't it? The core idea that the disease isn't fundamentally the vein, it's the atrium itself. Atrial myopathy.
AI 2:Precisely. And we can actually see it now with advanced imaging. LGE MRI scans can map out fibrosis, the scarring in the left atrium.
AI 1:And what does that show?
AI 2:It shows that once that scarring covers about 30% or more of the atrial wall, the chance of AF coming back jumps over fifty percent. Right. It's stark. We spent years perfecting tools to zap electrical triggers
Dr Niraj Sharma:Right.
AI 2:While maybe ignoring the underlying mechanical issues, the metabolism, the inflammation that was really driving the bus.
AI 1:Okay. So if we've hit a biological ceiling, the treatment has to evolve. Moving away from just lesion creation creation towards, disease modification, what does that look like in practice?
AI 2:It's gotta be multimodal. Right. A combined approach. First off, serious risk factor modification.
AI 1:Like diet and exercise.
AI 2:And more. Intensive weight loss, treating sleep apnea aggressively, tight blood pressure control, studies like ARREST AF actually show this can reverse some of the structural damage. You have to clean up the biological environment.
AI 1:Makes sense. So that's step one with step two, bringing that biology into the procedure itself.
AI 2:Exactly. Precision ablation Using those LGE MRI fibrosis maps during planning. So instead of a standard PDI pattern for everyone, you customize the ablation. You target the specific areas of scar tissue known to cause problems.
AI 1:Tailoring the treatment. And the third piece, pharmacology. Are there new drugs coming into play?
AI 2:Yeah. That's a really exciting area. Exploring agents like GLP one agonists, SGLT two inhibitors drugs, you might know from diabetes or weight loss.
AI 1:Right.
AI 2:They aren't traditional heart rhythm drugs, but they seem to tackle the metabolic side, the inflammation, the fat. They might reduce AF burden just by making the atrium healthier overall, working alongside the ablation.
AI 1:So putting it all together, the big takeaway here for you, listeners, seems to be ablation works best when the atrium is healthiest to begin with. Recurrence is basically fibrosis plus fat plus inflammation plus time.
AI 2:That's the equation we're dealing with. Yeah. And it really suggests the next big leap forward in treating AF probably won't be a slightly different catheter, you know, hotter, colder, faster pulses. Uh-huh. It's gonna come from truly understanding the biology and shifting to this comprehensive multimodal management, restoring atrial health.
AI 1:And that really challenges the traditional focus, which was heavily on the procedure itself, Which leads to, I guess, a final provocative thought. If future success depends so much on restoring atrial health, how much of the effective therapy needs to happen before a patient even steps into the EP lab?
Dr Niraj Sharma:And that brings us to the end of this month's EP Edge newsletter, November 2025 issue six. Today we walked through the fascinating evolution of atrial fibrillation management from the surgical Cox maze procedure to the discovery of pulmonary vein ectopy that reshaped our entire approach to rhythm control. We traced how Heisegwehr's seminal insight opened the door to catheter ablation, how Paponi's wide circumferential lesions redefined procedural strategy, and how energy sources evolved from radiofrequency to cryo and now to pulse field ablation. Yet as we have seen, despite new tools and new technologies, the ultimate success of ablation remains tied not just to our catheters or energy sources, but to the substrate we're treating. Atrial myopathy, fibrosis, inflammation, are not simply bystanders but active participants in arrhythmia, persistence, and recurrence.
Dr Niraj Sharma:Today's discussion reminded us that the future of AF therapy won't hinge solely on better ablation lines. It will depend on understanding the biology beneath the rhythm, the molecular signatures, the imaging correlates, and the interplay between inflammation, fibrosis, and electrical remodeling. As we look ahead, the next frontier lies in integrating these insights, combining precision electrophysiology with precision biology. Tools like AI driven mapping, tissue specific imaging and biomarker guided therapy may help us move from ablating triggers to reversing disease. The story of AF isn't finished, it's simply entering its next chapter.
Dr Niraj Sharma:Thank you for joining me on this journey. For infographics, data sources, and full references visit the EP Edge LinkedIn newsletter. If you have any questions, feedback or suggestions I would love to hear from you. Just email me at EPEdgecastgmail dot com and don't forget to subscribe, share and follow the EP Edge podcast wherever you listen. Till next time this is Doctor.
Dr Niraj Sharma:Niraj Sharma signing off. Take care and bye for now.